Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 5, 2010, Pages 737-743

  Cassidy, James ^a   Saltz, Leonard B ^b   Giantonio, Bruce J ^c   Kabbinavar, Fairooz F ^d   Hurwitz, Herbert I ^e   Rohr, Ulrich Peter ^f  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bevacizumab; Chemotherapy; Metastatic colorectal cancer; Older patients; Pooled analysis

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ABSCESS; ADULT; AGE; AGED; ARTERY THROMBOEMBOLISM; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; FISTULA; HUMAN; HYPERTENSION; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; WOUND HEALING; ADOLESCENT; COLORECTAL TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 77950494294     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0712-3     Document Type: Article

References (15)

1. Abbott RD, Curb JD, Rodriguez BL, Masaki KH, Popper JS, Ross GW, Petrovitch H (2003) Age-related changes in risk factor effects on the incidence of thromboembolic and hemorrhagic stroke. J Clin Epidemiol 56:479-486
2. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, Wingo PA, Jemal A, Feigal EG (2002) Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94:2766-2792
3. Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H, Köhne CH (2004) Efficacy of 5-Xuorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15:1330-1338
4. Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E, Rougier P, Mitry E, Schubert U, Köhne CH (2008) Irinotecan/Xuorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 26:1443-1451
5. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd, Eastern Cooperative Oncology Group Study E3200 (2007) Bevacizumab in combination with oxaliplatin, Xuorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544
6. Goldberg RJ, Gore JM, Gurwitz JH, Alpert JS, Brady P, Strohsnitter W, Chen ZY, Dalen JE (1989) The impact of age on the incidence and prognosis of initial acute myocardial infarction: the Worcester Heart Attack Study. Am Heart J 117:543-549
7. Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ (2006) Pooled analysis of safety and efficacy of oxaliplatin plus Xuorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085-4091
8. Hurwitz H, Saini S (2006) Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 33(5 Suppl 10):S26-S34
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, Xuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
10. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S (2005) Combined analysis of efficacy: the addition of bevacizumab to Xuorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712
11. Kabbinavar F, Hurwitz H, Yi J, Rosen O (2009) Addition of bevacizumab to Xuorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized trials. J Clin Oncol 27:199-205
12. KozloV MF, Sugrue M, Purdie DM, Flynn PJ, Kabbinavar F, Sargent D, Purdie DM, Dong W, Grothey A (2008) Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): results from the BRiTE observational cohort study. J Clin Oncol 26(15S):Abstract 4026.
13. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008) Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019
14. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232-1239
15. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585-593